论文部分内容阅读
目的:观察黄葵胶囊联合缬沙坦治疗糖尿病肾病的临床效果。方法:回顾性分析2012年8月-2014年12月治疗的100例糖尿病肾病患者,随机分为对照组和实验组,对照组服用缬沙坦胶囊,实验组在对照组的基础上服用黄葵胶囊,连续治疗6周后记录两组患者在治疗前后的尿白蛋白排泄率(UAER)、总胆固醇(TC)、甘油三酯(TG)和肌酐(Scr)4项指标及不良反应。结果:实验组患者治疗后的UAER、TC、TG改善均优于对照组,差异具有统计学意义(P<0.05),实验组Scr水平与对照组比较,差异无统计学意义(P>0.05),两组患者均未出现严重的不良反应。结论:黄葵胶囊联合缬沙坦能够有效治疗糖尿病肾病,而且无明显的不良反应。
Objective: To observe the clinical efficacy of Huang Kui capsule combined with valsartan in the treatment of diabetic nephropathy. Methods: One hundred patients with diabetic nephropathy who were treated from August 2012 to December 2014 were retrospectively analyzed. Patients in the control group were treated with valsartan capsules. The experimental group was given the control group with Huang Kui Capsule, continuous treatment for 6 weeks after treatment records urinary albumin excretion rate (UAER), total cholesterol (TC), triglyceride (TG) and creatinine (Scr) 4 indicators and adverse reactions. Results: The improvement of UAER, TC and TG in the experimental group was better than that in the control group (P <0.05). There was no significant difference in Scr level between the experimental group and the control group (P> 0.05) No serious adverse reactions occurred in both groups. Conclusion: Huang Kui capsule combined with valsartan can effectively treat diabetic nephropathy, and no obvious adverse reactions.